13F data — long US equity only · ~45-day lag from quarter-end · positions may have changed since · not investment advice
← Strongest buys
10

ZTS

ZOETIS INC · Health Care

Consensus score 10/100 · #47 this quarter · tier-weighted across tracked managers

DivergingPrice action since filingas of 2026-07-10
vs 50-day avg
-7.9%
21-day momentum
-8.1%
recent volume
0.94×

13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.

S4· DecliningStage Analysis · Weinstein
vs 30-wk avg
-30.7%
30-wk MA slope
-5.6%
rel. strength
-41.0
52-wk range
5%

Declining — below a falling 30-week trend, lagging the market. Weinstein says avoid. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.

Holders
4
tracked managers
New this Q
1
opened a position
Avg weight
3.6%
of their portfolios
Combined value
$1.26B
held, at quarter-end

Who’s holding it Q1 2026, by position size

ManagerPosition sizeChange
Ruane Cunniff / Sequoia
Quality compounder
4.8%
NEW
Fundsmith
Concentrated
3.6%
TRIM
Polen Capital
Quality growth
3.5%
TRIM
Wedgewood Partners
Quality growth
2.8%
ADD

Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.